Drug Side Effects
Search
DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)
0 reported adverse events
Drug classes:
CD38-directed Cytolytic Antibody [EPC]
Endoglycosidase [EPC]
These side effects are most commonly reported by patients taking DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT):
#
Side effect
Count
See all common reactions for DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)
DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT) is most commonly taken among patients reporting these side effects:
#
Side effect
Count
Frequency
See all enriched reactions for DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)